Theralac Strains -- Clinical Studies
This Report Just Published in the Journal of Medical Microbiology:
If the above link will not open, you need Adobe Reader.
Other well-known clinical studies:
THERALAC’S CLINICALLY PROVEN PROBIOTIC STRAINS - 6/11/09 edition
Lactobacillus acidophilus LA-1 (also called NCFM) ----> 10 billion CFU/capsule
• Reduces diarrhea in children: Pediatr. Res. 1996; 39 (Part 2): p104
• Reduces traveler’s diarrhea: Travel Medicine 1989; Vol1: p333
• Reduces lactose intolerance: J. Dairy Sci. 1995; 78: P1657
• Reduces symptoms of bowel infections: J. Am. Soc. Nephrol. 1998; 9: p146
Lactobacillus paracasei F-19 ----> 5 billion CFU/capsule
• Effect on C. Diff. colonization in elderly persons: Anaerobe 2001; 7: p 67
• Effect on H. pylori infections in children and elderly: in Microbial Ecology in Health and Disease 2002; 14 (Suppl. 3), p17
• Survival and safety in human G.I. tract: in Microbial Ecology in Health and Disease 2002; 14 (Suppl. 3), p22
Bifidobacterium lactis BL-34 (also called Bl-04) ----> 10 billion CFU/capsule
• Restores beneficial microflora after antibiotic treatment: J. Medical Microbiology 2009; 58, p663 (randomized, double blind, controlled study).
• Demonstrates synergy with prebiotic soluble fiber: Clinical Infectious Diseases 2005; 40: p28
• Modulates immune system in human subjects: World J. Gastroenterology 2007; 13 (2): p236 and FEMS Immunology and Medical Microbiology 2003; 38: p165
Bifidobacterium lactis Bi-07 ----> 3 billion CFU/capsule
• Modulates immune system in human subjects: World J. Gastroenterology 2007; 13 (2): p236 and FEMS Immunology and Medical Microbiology 2003; 38: p236
• Reduces diarrhea in children: Pediatr. Res. 1996; 39 (Part 2): p104
• Restores beneficial microflora after antibiotic treatment: J. Medical Microbiology 2009; 58, p663 (randomized, double blind, controlled study).
NOTE: THERALAC® IS PROTECTED BY U.S. PATENTS 7,122,370 AND 7,229,818 THAT ASSURE VIABLE DELIVERY OF ITS PROBIOTIC STRAINS THROUGH STOMACH ACID.